登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002940 证券简称：昂利康 公告编号：2026-002 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、本期业绩预计情况 1、业绩预告期间：2025年1月1日至2025年12月31日。 2、业绩预告情况：自愿性业绩预告 （1）以区间数进行业绩预告的 单位：万元 二、与会计师事务所沟通情况 本次业绩预告是公司财务部门初步测算结果，未经会计师事务所审计。但公司已就业绩预告有关重大事 项与年度审计会计师事务所进行了预沟通，截至目前，公司与会计师事务所在本报告期的业绩预告方面 不存在重大分歧。 公司预计2025年度归属于上市公司股东的净利润为11,000万元～13,800万元，同比增长36.93%～ 71.78%。主要原因如下： 1、2025年度公司研发费用支出较上年同期相比减少。一是2025年度公司减少仿制药研发项目的新增立 项，相应研发支出下降；二是亚飞（上海）生物医药科技股份有限公司（包括其子公司上海亲合力生物 医药科技股份有限公司）尚未完成公司与其达成的关于ALK-N002创新药项目战略合作协 ...

Company Overview - Zhejiang Anglikang Pharmaceutical Co., Ltd. is located at 1000 North Shengzhou Avenue, Shengzhou City, Zhejiang Province, established on December 30, 2001, and listed on October 23, 2018. The company's main business involves the research, production, and sales of chemical raw materials and formulations [1][2]. Financial Performance - As of March 31, 2025, Anglikang reported a revenue of 346 million yuan, a year-on-year decrease of 15.31%, and a net profit attributable to shareholders of 15.91 million yuan, down 43.63% year-on-year [2]. - The company has cumulatively distributed 341 million yuan in dividends since its A-share listing, with 108 million yuan distributed over the past three years [3]. Stock Performance - On August 27, Anglikang's stock price fell by 2.04% to 51.80 yuan per share, with a trading volume of 303 million yuan and a turnover rate of 3.11%, resulting in a total market capitalization of 10.45 billion yuan [1]. - Year-to-date, Anglikang's stock price has increased by 296.69%, with a 4.75% rise over the last five trading days, a 0.38% decline over the last 20 days, and a 209.85% increase over the last 60 days [1]. Shareholder Information - As of March 31, 2025, Anglikang had 12,300 shareholders, an increase of 10.23% from the previous period, with an average of 15,104 circulating shares per shareholder, a decrease of 9.28% [2]. - Among the top ten circulating shareholders, Xinyi Medical Care A (011466) ranked as the eighth largest, holding 1.1006 million shares, a decrease of 288,300 shares from the previous period [3]. Industry Classification - Anglikang belongs to the pharmaceutical and biological industry, specifically in the chemical pharmaceutical and chemical formulation sectors. The company is associated with concepts such as ursodeoxycholic acid, hypertension treatment, Helicobacter pylori concepts, synthetic biology, and innovative drugs [2].